For US Healthcare Professionals Only
Filter
Unmet needs in atopic dermatitis treated with current biologic therapies: results from an international cross-sectional cohort study
Bimekizumab safety and sustained long-term efficacy in patients with active psoriatic arthritis and baseline psoriasis: Up to 3-year results from two phase 3 studies
Bimekizumab pharmacokinetics, safety, and efficacy in adolescents with moderate to severe plaque psoriasis: Data from the initial treatment period of the open-label BE CONNECTED phase 2 study
Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment
Bimekizumab time to clinical response and achievement of clinically meaningful improvement thresholds in Chinese patients with psoriasis from the BE SHINING phase 3 trial
Bimekizumab Efficacy by Disease Duration and Severity in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results From BE HEARD EXT
Bimekizumab Leads to Sustained Flare-Free Status in Moderate to Severe Hidradenitis Suppurativa: 3-Year Data from BE HEARD EXT
Bimekizumab Efficacy by Patient Subgroups in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results From BE HEARD EXT
Bimekizumab on-treatment remission as defined by the National Psoriasis Foundation: 1-year results versus ustekinumab and secukinumab in patients with moderate to severe plaque psoriasis
Bimekizumab treatment resulted in long-term maintenance of complete clinical resolution across skin, joint, and nail domains in patients with active psoriatic arthritis: 3-year results from two phase 3 studies
Bimekizumab Demonstrates Sustained Improvements in Pain, Morning Stiffness, and Fatigue in Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies
Bimekizumab Efficacy on IHS4 Response Levels and Lesions by HS Disease Duration Over 2 Years: Data from BE HEARD EXT